Arthur Pettigrew, MD
Family Medicine · Bolingbrook, ILNPI 1699824482
Payments from drug & device makers
Across 91 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$297
- Novo Nordisk$198
- Amarin Pharma, Inc.$185
- Astellas Pharma US Inc$182
- Amgen$176
- AbbVie$120
- plus $850 from 20 others
What the payments were for
- Food & beverage$1,86393%
- Education$1457%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $297 |
| Novo Nordisk | 9 | $198 |
| Amarin Pharma, Inc. | 8 | $185 |
| Astellas Pharma US Inc | 7 | $182 |
| Amgen | 9 | $176 |
| AbbVie(2 entities) | 5 | $120 |
| Pfizer | 6 | $119 |
| Boehringer Ingelheim | 6 | $109 |
| Dexcom, Inc. | 3 | $70 |
| AstraZeneca | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Bayer | 2 | $51 |
| Johnson & Johnson | 2 | $49 |
| GSK | 2 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Merck | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Corcept Therapeutics | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$120
How this compares
$2,008 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $99,462 |
| JardianceEmpagliflozin | 71 | $94,702 |
| OzempicSemaglutide | 56 | $74,968 |
| FarxigaDapagliflozin Propanediol | 37 | $40,107 |
| TrulicityDulaglutide | 22 | $28,770 |
| JanuviaSitagliptin Phosphate | 22 | $27,677 |
| MounjaroTirzepatide | 16 | $23,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,060 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $18,118 |
| XareltoRivaroxaban | 15 | $17,809 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $11,700 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $11,313 |
| VascepaIcosapent Ethyl | 12 | $9,793 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $8,138 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $6,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $119 | $99,46276 claims |
| Boehringer IngelheimJardiance | $109 | $94,70271 claims |
| Novo NordiskOzempic | $198 | $74,96856 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $297 | $51,85838 claims |
| AstraZenecaFarxiga, Symbicort | $57 | $44,84455 claims |
| MerckJanuvia | $26 | $27,67722 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $49 | $25,44441 claims |
| Johnson & JohnsonXarelto | $49 | $17,80915 claims |
| AbbVieSynthroid | $120 | $1,41617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Bolingbrook
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.